SCHEMBL449084

SCHEMBL449084

COc1ccc(S(=O)(=O)N(C)C(C)c2nc3ccccc3c(=O)n2-c2cc(C)cc(C)c2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR3 P49682 2/20 0.47
ALDH1A1 P00352 5/20 0.47
RAB9A P51151 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
C1R P00736 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.44
LMNA P02545 2/20 0.44
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
CYP1A2 P05177 2/20 0.42
CYP2C9 P11712 2/20 0.42
CYP2C19 P33261 2/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
G6PD P11413 1/20 0.42
RECQL P46063 1/20 0.42
POLB P06746 2/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
APOBEC3G Q9HC16 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL451703 0.92 ALDH1A1 (0.58) CXCR3ALDH1A1RAB9ANPSR1C1R
SCHEMBL454301 0.91 CXCR3 (0.47) CXCR3ALDH1A1NPSR1C1RSMN1; SMN2
SCHEMBL448756 0.91 CXCR3 (0.53) CXCR3ALDH1A1RAB9ANPSR1C1R
SCHEMBL451745 0.91 CXCR3 (0.55) CXCR3ALDH1A1RAB9ANPSR1C1R
SCHEMBL452526 0.91 CXCR3 (0.44) CXCR3ALDH1A1SMN1; SMN2LMNAMEN1
SCHEMBL448940 0.90 CXCR3 (0.45) CXCR3ALDH1A1C1RLMNAMEN1
SCHEMBL451961 0.89 HTR6 (0.45) CXCR3ALDH1A1NPSR1C1RSMN1; SMN2
SCHEMBL452088 0.89 CXCR3 (0.41) CXCR3ALDH1A1C1RLMNAMEN1
SCHEMBL448997 0.87 SMN1; SMN2 (0.53) CXCR3ALDH1A1RAB9ANPSR1C1R
SCHEMBL452231 0.87 CXCR3 (0.51) CXCR3ALDH1A1RAB9ANPSR1C1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748440-B2 Quinazolinone modulators of nuclear receptors EXELIXIS, INC. (US) 2014-06-10 US claimed
US-20120064025-A1 Quinazolinone Modulators Of Nuclear Receptors EXELIXIS, INC. (US) 2012-03-15 US claimed
EP-1521746-B1 QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS X CEPTOR THERAPEUTICS INC (US) 2011-04-27 EP claimed
US-20080070864-A1 Quinazolinone Modulators Of Nuclear Receptors X-CEPTOR THERAPEUTICS, INC. (US) 2008-03-20 US claimed
US-8748440-B2 Quinazolinone modulators of nuclear receptors EXELIXIS, INC. (US) 2014-06-10 US disclosed
US-20120064025-A1 Quinazolinone Modulators Of Nuclear Receptors EXELIXIS, INC. (US) 2012-03-15 US disclosed
EP-1521746-B1 QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS X CEPTOR THERAPEUTICS INC (US) 2011-04-27 EP disclosed
US-20080070864-A1 Quinazolinone Modulators Of Nuclear Receptors X-CEPTOR THERAPEUTICS, INC. (US) 2008-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120064025-A1 Quinazolinone Modulators Of Nuclear Receptors NR1H4, NR1H2, NR1H3 CXCR3 741/4885ALDH1A1 3161/4885RAB9A 1349/4885
US-20080070864-A1 Quinazolinone Modulators Of Nuclear Receptors NR1H4, NR1H2, NR1H3 CXCR3 741/4885ALDH1A1 3161/4885RAB9A 1349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.